000281356 001__ 281356
000281356 005__ 20251012002034.0
000281356 0247_ $$2doi$$a10.1038/s41531-025-01115-8
000281356 0247_ $$2pmid$$apmid:40954161
000281356 0247_ $$2pmc$$apmc:PMC12436598
000281356 0247_ $$2altmetric$$aaltmetric:181428837
000281356 037__ $$aDZNE-2025-01103
000281356 041__ $$aEnglish
000281356 082__ $$a610
000281356 1001_ $$aDrwesh, Layla$$b0
000281356 245__ $$aMethodological validation of Miro1 retention as a candidate Parkinson's disease biomarker.
000281356 260__ $$a[London]$$bSpringer Nature$$c2025
000281356 3367_ $$2DRIVER$$aarticle
000281356 3367_ $$2DataCite$$aOutput Types/Journal article
000281356 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759826182_17317
000281356 3367_ $$2BibTeX$$aARTICLE
000281356 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281356 3367_ $$00$$2EndNote$$aJournal Article
000281356 520__ $$aMitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.
000281356 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281356 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000281356 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281356 7001_ $$aArena, Giuseppe$$b1
000281356 7001_ $$aMerk, Daniel J$$b2
000281356 7001_ $$aFerrante, Daniele$$b3
000281356 7001_ $$aGorgogietas, Vyron$$b4
000281356 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b5$$udzne
000281356 7001_ $$aGrünewald, Anne$$b6
000281356 7001_ $$aMay, Patrick$$b7
000281356 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b8$$udzne
000281356 7001_ $$aKrüger, Rejko$$b9
000281356 7001_ $$aWüst, Richard$$b10
000281356 7001_ $$0P:(DE-2719)2811291$$aGloeckner, Christian Johannes$$b11$$udzne
000281356 7001_ $$aFitzgerald, Julia C$$b12
000281356 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-025-01115-8$$gVol. 11, no. 1, p. 270$$n1$$p270$$tnpj Parkinson's Disease$$v11$$x2373-8057$$y2025
000281356 8564_ $$uhttps://pub.dzne.de/record/281356/files/DZNE-2025-01103%20SUP.zip
000281356 8564_ $$uhttps://pub.dzne.de/record/281356/files/DZNE-2025-01103.pdf$$yOpenAccess
000281356 8564_ $$uhttps://pub.dzne.de/record/281356/files/DZNE-2025-01103.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281356 909CO $$ooai:pub.dzne.de:281356$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281356 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000281356 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000281356 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811291$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000281356 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281356 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000281356 9141_ $$y2025
000281356 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000281356 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281356 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:43:48Z
000281356 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:43:48Z
000281356 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281356 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:43:48Z
000281356 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000281356 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000281356 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000281356 9201_ $$0I:(DE-2719)1210007$$kAG Gloeckner$$lFunctional Neuroproteomics and Translational Biomarkers in Neurodegenerative Diseases$$x1
000281356 980__ $$ajournal
000281356 980__ $$aVDB
000281356 980__ $$aUNRESTRICTED
000281356 980__ $$aI:(DE-2719)1210000
000281356 980__ $$aI:(DE-2719)1210007
000281356 9801_ $$aFullTexts